My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Pfizer (NY:PFE)

26.68 -0.70 (-2.54%)

Streaming Delayed Price Updated: 1:51 PM EST, Feb 19, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Pfizer’s BRAFTOVI BREAKWATER Trial Delivers Landmark Survival Gains in Colorectal Cancer

Today 10:33 EST

NEW YORK — Pfizer Inc. (NYSE: PFE) has announced breakthrough results from its Phase 3 BREAKWATER clinical trial, demonstrating that its BRAFTOVI (encorafenib) regimen significantly improves both...

Via MarketMinute

Top High-Yield Stocks to Double Up on Right Now ↗

Today 9:34 EST

If you are looking for high-yield stocks, these two turnaround stories offer yield and green shoots, suggesting better times are ahead.

Via The Motley Fool

Nasdaq, S&P 500 Futures Edge Higher, Trump Speech In Focus: Why WMT, META, IBRX, MSFT, EBAY Are On Traders' Radar Today ↗

Today 4:18 EST

Data from Stocktwits indicated retail sentiment towards SPY and QQQ cooled to neutral.

Via Stocktwits

Topics ETFs Economy Government

2 Large-Cap Stocks on Our Watchlist and 1 We Brush Off

February 18, 2026

Large-cap stocks usually command their industries because they have the scale to drive market trends. The flip side though is that their sheer size can limit growth as expanding further becomes an...

Via StockStory

MoonLake Stock Soars As Biotech Fund Reloads, Takeover Chatter Ignites ↗

February 17, 2026

Optimism also grew around FDA momentum for its palmoplantar pustulosis drug ahead of MoonLake’s Feb. 23 investor day.

Via Stocktwits

1 Reason I'd Buy Eli Lilly Stock and Never Sell ↗

February 17, 2026

A robust pipeline is essential for a buy-and-hold pharmaceutical stock.

Via The Motley Fool

Topics Intellectual Property

Pfizer's Cancer Drug Combo Shows Strong Results In Key Colorecatal Cancer Trial ↗

February 17, 2026

Pfizer's Braftovi combo improves survival in advanced colorectal cancer trial.

Via Benzinga

Moderna’s mRNA Renaissance: Navigating Volatility and the Post-Pandemic Pipeline

February 17, 2026

As of February 17, 2026, Moderna, Inc. (NASDAQ:MRNA) finds itself at a pivotal crossroads in its corporate evolution. Long defined by its meteoric rise during the COVID-19 pandemic, the Cambridge-based...

Via Finterra

Topics Economy Intellectual Property

Pfizer’s BRAFTOVI Regimen Improves Progression-Free Survival in Metastatic Colorectal Cancer

February 17, 2026

From Pfizer Inc.

Via Business Wire

2 S&P 500 Stocks to Research Further and 1 We Question

February 16, 2026

While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural...

Via StockStory

Topics Stocks

2 Value Stocks Worth Your Attention and 1 We Brush Off

February 16, 2026

Value investing has produced some of the world’s most famous investing billionaires, including Warren Buffett, David Einhorn, and Seth Klarman, who built their fortunes by purchasing wonderful...

Via StockStory

The Great Inflation Thaw: US Price Pressures Hit Five-Year Low as Federal Reserve Eyes 2026 Pivot

February 16, 2026

The United States economy reached a long-awaited milestone this week as the Bureau of Labor Statistics reported that headline inflation fell to 2.4% in January 2026, with the core Consumer Price Index...

Via MarketMinute

Topics Artificial Intelligence Bonds Economy

ASCO GU 2026: Merck and Protara Poised to Disrupt Bladder and Kidney Cancer Standards

February 16, 2026

As the oncology community prepares to descend upon San Francisco for the 2026 ASCO Genitourinary (GU) Cancers Symposium from February 26–28, investors and clinicians alike are bracing for data that...

Via MarketMinute

Topics Intellectual Property

3 S&P 500 Stocks Worth Investigating

February 15, 2026

The S&P 500 (^GSPC) is packed with companies that have built dominant market positions, making it a core index for investors. A select few continue to innovate and expand, setting themselves up for...

Via StockStory

Topics Stocks

What Is One of the Best Pharmaceutical Stocks to Own for the Next 10 Years? ↗

February 14, 2026

Eli Lilly continues to pursue smart acquisitions for the long term.

Via The Motley Fool

Topics Intellectual Property

Moderna Shares Surge as Aggressive Cost-Cutting and Post-Pandemic Pivot Take Hold in Q4 Results

February 13, 2026

Moderna Inc. (NASDAQ: MRNA) shares jumped 8% in early trading on February 13, 2026, after the biotechnology pioneer reported fourth-quarter 2025 financial results that exceeded Wall Street’s...

Via MarketMinute

Topics Earnings

Hospitals Stand Tall: Healthcare Sector Becomes Safe Haven Amid "Warsh Shock" and Tech Volatility

February 13, 2026

In a day defined by sharp reversals and a fundamental recalibration of market leadership, the healthcare sector emerged as the primary beneficiary of a massive capital rotation on February 13, 2026....

Via MarketMinute

Topics Artificial Intelligence Earnings Economy

The Great 2026 Divergence: Tech Titans Rise on AI Execution While Healthcare Reaps a Regulatory Whirlwind

February 13, 2026

As the opening bell rang on February 13, 2026, the divergence between the U.S. technology and healthcare sectors reached a historic fever pitch, signaling a fundamental shift in how markets price...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

Meet the 6.3% Yield Dividend Stock That Could Soar in 2026 ↗

February 13, 2026

Pfizer's long-acting GLP-1 weight loss candidate could set the stage for a stock rally.

Via The Motley Fool

Topics Intellectual Property

Healthcare’s Renaissance: Sector Outshines Tech as Policy Clarity Sparks Q4 Surge

February 12, 2026

The healthcare sector has staged a dramatic structural breakout, ending a multi-year period of relative stagnation to lead the global markets into 2026. After a powerful 10% gain in the final quarter...

Via MarketMinute

Topics Artificial Intelligence Economy World Trade

S&P 500 Breaches 7,000 Milestone: AI Megacaps Propel Market to Historic Heights

February 12, 2026

The financial world witnessed a watershed moment on January 28, 2026, as the S&P 500 index breached the 7,000-point threshold for the first time in history. This milestone, coming just fourteen months...

Via MarketMinute

Topics Artificial Intelligence Economy Stocks

Alnylam Pharmaceuticals (ALNY): The RNAi Pioneer’s 2026 Breakout and the Battle for Cardiovascular Dominance

February 12, 2026

As of February 12, 2026, Alnylam Pharmaceuticals (NASDAQ: ALNY) has officially transcended its status as a high-potential biotech and entered the pantheon of global pharmaceutical powerhouses. Known as...

Via Finterra

Topics Economy Intellectual Property

Zoetis Inc. (ZTS): Navigating Innovation and Safety in a Mature Animal Health Market

February 12, 2026

Zoetis Inc. (NYSE: ZTS) stands today as the undisputed global leader in animal health, a position it has fortified since its historic decoupling from Pfizer over a decade ago. As of February 12, 2026,...

Via Finterra

Topics Artificial Intelligence Earnings Economy

FDA Stuns Moderna with Refusal to Review Flu Vaccine, Sending Shares Tumbling 3.5%

February 12, 2026

Shares of Moderna, Inc. (NASDAQ: MRNA) fell 3.5% on February 12, 2026, as investors continued to digest the fallout from a rare and unexpected regulatory setback. The U.S. Food and Drug Administration...

Via MarketMinute

Topics Earnings

Zoetis’s (NYSE:ZTS) Q4 CY2025 Sales Top Estimates

February 12, 2026

Animal health company Zoetis (NYSE:ZTS) announced better-than-expected revenue in Q4 CY2025, with sales up 3% year on year to $2.39 billion. The company expects the full year’s revenue to be around...

Via StockStory

Pfizer Reports Strong Earnings Outlook - Unusual Call Options Activity Shows Investors Are Bullish ↗

February 11, 2026

Pfizer, Inc. reported strong earnings and earnings guidance on Feb. 3. Large, unusual call option activity today shows that investors are bullish.

Via Talk Markets

Is Now the Best Time to Buy Pfizer Stock? ↗

February 11, 2026

It's worth taking a second look at the healthcare giant.

Via The Motley Fool

Topics Intellectual Property

Pfizer Reports Strong Earnings Outlook - Unusual Call Options Activity Shows Investors are Bullish

February 11, 2026

Pfizer reported strong earnings and earnings guidance. Large, unusual call option activity today, as noted in a Barchart report, indicates investors are bullish.

Via Barchart.com

Healthcare Stocks Are Sinking. Here Are 2 to Buy on the Dip. ↗

February 11, 2026

Eli Lilly is priced for perfection thanks to its GLP-1 drugs, while Wall Street seems to have forgotten about these two high-yield healthcare stocks.

Via The Motley Fool

Moderna (MRNA) Deep Dive: Navigating Regulatory Blows and the Pivot to Oncology

February 11, 2026

Today, February 11, 2026, marks a volatile chapter for Moderna, Inc. (NASDAQ: MRNA). The biotechnology pioneer, which became a household name during the COVID-19 pandemic, finds itself at a critical...

Via Finterra

Topics Artificial Intelligence Initial Public Offering Intellectual Property

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.